Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland; Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland; Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Vet Microbiol. 2018 Apr;217:112-120. doi: 10.1016/j.vetmic.2018.03.006. Epub 2018 Mar 10.
Mycoplasma haemofelis is the most pathogenic feline hemoplasma species and a causative agent of infectious hemolytic anemia in cats. Current treatment protocols are effective in reducing M. haemofelis blood loads and clinical signs but consistent bacteremia clearance is rarely achieved. The aim of this study was to develop an antibiotic treatment protocol capable of clearing M. haemofelis bacteremia. Doxycycline and marbofloxacin treatment protocols were evaluated in chronically M. haemofelis infected cats in two pre-experiments and a controlled treatment study (main experiment) using five treated and four untreated cats. The blood bacterial loads in the main experiment were monitored weekly by real-time PCR for 203 days. Cats were treated with doxycycline (5 mg/kg bid orally) for 28 days. Cats that remained M. haemofelis PCR-positive or became positive again (all 5 cats in the main experiment) were switched to marbofloxacin treatment (2 mg/kg sid orally) for 14 days; then, all cats were PCR-negative. Immunosuppression after the antibiotic treatment did not lead to reactivation of bacteremia. Fine needle aspirates of different organs and bone marrow collected before and after immunosuppression were PCR-negative. Overall, 5 cats cleared bacteremia with doxycycline alone (showing lower bacterial loads at the treatment start), while 10 cats needed to be switched to marbofloxacin. Based on our results, we recommend doxycycline treatment (10 mg/kg up to 28 days) for clearance of M. haemofelis infection and monitoring bacterial loads by real-time PCR. Only if bacteremia persists or reoccurs, antibiotic treatment should be switched to marbofloxacin (2 mg/kg sid for 14 days).
猫血巴尔通体是最具致病性的猫血支原体物种,也是猫传染性溶血性贫血的病原体。目前的治疗方案可有效降低猫血巴尔通体的血液载量和临床症状,但很少能实现持续清除菌血症。本研究旨在开发一种能够清除猫血巴尔通体菌血症的抗生素治疗方案。在两项预实验和一项对照治疗研究(主要实验)中,评估了多西环素和马波沙星治疗方案,该研究使用了 5 只治疗猫和 4 只未治疗猫。主要实验中,每周通过实时 PCR 监测血液细菌负荷 203 天。猫接受多西环素(5mg/kg,bid,口服)治疗 28 天。在主要实验中,所有 5 只猫仍为猫血巴尔通体 PCR 阳性或再次呈阳性的猫(所有猫)均转为马波沙星治疗(2mg/kg,sid,口服)14 天;然后,所有猫均为 PCR 阴性。抗生素治疗后的免疫抑制并未导致菌血症再激活。在免疫抑制前后采集的不同器官和骨髓的细针抽吸物均为 PCR 阴性。总的来说,5 只猫单独使用多西环素清除了菌血症(治疗开始时细菌载量较低),而 10 只猫需要转为马波沙星治疗。基于我们的结果,我们建议使用多西环素(10mg/kg,持续 28 天)治疗以清除猫血巴尔通体感染,并通过实时 PCR 监测细菌载量。只有在菌血症持续存在或再次发生时,才应将抗生素治疗方案转换为马波沙星(2mg/kg,sid,持续 14 天)。